Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 126

1.

Overexpression of ubiquitin-specific peptidase 15 in systemic sclerosis fibroblasts increases response to transforming growth factor β.

Galant C, Marchandise J, Stoenoiu MS, Ducreux J, De Groof A, Pirenne S, Van den Eynde B, Houssiau FA, Lauwerys BR.

Rheumatology (Oxford). 2019 Apr 1;58(4):708-718. doi: 10.1093/rheumatology/key401.

2.

Ustekinumab: a promising new drug for SLE?

Costedoat-Chalumeau N, Houssiau FA.

Lancet. 2018 Oct 13;392(10155):1284-1286. doi: 10.1016/S0140-6736(18)32330-4. Epub 2018 Sep 21. No abstract available.

PMID:
30249508
3.

Establishing Surrogate Kidney End Points for Lupus Nephritis Clinical Trials: Development and Validation of a Novel Approach to Predict Future Kidney Outcomes.

Mackay M, Dall'Era M, Fishbein J, Kalunian K, Lesser M, Sanchez-Guerrero J, Levy DM, Silverman E, Petri M, Arriens C, Lewis EJ, Korbet SM, Conti F, Tesar V, Hruskova Z, Borba EF, Bonfa E, Chan TM, Rathi M, Gupta KL, Jha V, Hasni S, West MR, Solomons N, Houssiau FA, Romero-Diaz J, Mejia-Vilet J, Rovin BH.

Arthritis Rheumatol. 2019 Mar;71(3):411-419. doi: 10.1002/art.40724. Epub 2019 Feb 1.

PMID:
30225865
4.

Intrarenal activation of adaptive immune effectors is associated with tubular damage and impaired renal function in lupus nephritis.

Pamfil C, Makowska Z, De Groof A, Tilman G, Babaei S, Galant C, Montigny P, Demoulin N, Jadoul M, Aydin S, Lesche R, McDonald F, Houssiau FA, Lauwerys BR.

Ann Rheum Dis. 2018 Dec;77(12):1782-1789. doi: 10.1136/annrheumdis-2018-213485. Epub 2018 Jul 31.

5.

Time to change the primary outcome of lupus trials.

Houssiau FA.

Ann Rheum Dis. 2019 May;78(5):581-582. doi: 10.1136/annrheumdis-2018-213788. Epub 2018 Jun 19. No abstract available.

PMID:
29921574
6.

Disease severity of proliferative lupus nephritis in Maghrebians.

Tamirou F, Costedoat-Chalumeau N, Medkouri G, Daugas E, Hachulla E, Jourde-Chiche N, Karras A, le Guern V, Gnemmi V, Jadoul M, Houssiau FA.

Lupus. 2018 Jul;27(8):1387-1392. doi: 10.1177/0961203318772016. Epub 2018 Apr 27.

PMID:
29703123
7.

International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus.

Kleinmann JF, Tubach F, Le Guern V, Mathian A, Richez C, Saadoun D, Sacre K, Sellam J, Seror R, Amoura Z, Andres E, Audia S, Bader-Meunier B, Blaison G, Bonnotte B, Cacoub P, Caillard S, Chiche L, Chosidow O, Costedoat-Chalumeau N, Daien C, Daugas E, Derdèche N, Doria A, Fain O, Fakhouri F, Farge D, Gabay C, Guillo S, Hachulla E, Hajjaj-Hassouni N, Hamidou M, Houssiau FA, Jourde-Chiche N, Koné-Paut I, Ladjouz-Rezig A, Lambotte O, Lipsker D, Mariette X, Martin-Silva N, Martin T, Maurier F, Meckenstock R, Mékinian A, Meyer O, Mohamed S, Morel J, Moulin B, Mulleman D, Papo T, Poindron V, Puéchal X, Punzi L, Quartier P, Sailler L, Smail A, Soubrier M, Sparsa A, Tazi-Mezalek Z, Zakraoui L, Zuily S, Sibilia J, Gottenberg JE.

Autoimmun Rev. 2017 Jun;16(6):650-657. doi: 10.1016/j.autrev.2017.04.011. Epub 2017 Apr 18.

PMID:
28434948
8.

Brief Report: The Euro-Lupus Low-Dose Intravenous Cyclophosphamide Regimen Does Not Impact the Ovarian Reserve, as Measured by Serum Levels of Anti-Müllerian Hormone.

Tamirou F, Husson SN, Gruson D, Debiève F, Lauwerys BR, Houssiau FA.

Arthritis Rheumatol. 2017 Jun;69(6):1267-1271. doi: 10.1002/art.40079. Epub 2017 May 3.

9.

Off-label use of rituximab for systemic lupus erythematosus in Europe.

Rydén-Aulin M, Boumpas D, Bultink I, Callejas Rubio JL, Caminal-Montero L, Castro A, Colodro Ruiz A, Doria A, Dörner T, Gonzalez-Echavarri C, Gremese E, Houssiau FA, Huizinga T, Inanç M, Isenberg D, Iuliano A, Jacobsen S, Jimenéz-Alonso J, Kovács L, Mariette X, Mosca M, Nived O, Oristrell J, Ramos-Casals M, Rascón J, Ruiz-Irastorza G, Sáez-Comet L, Salvador Cervelló G, Sebastiani GD, Squatrito D, Szücs G, Voskuyl A, van Vollenhoven R.

Lupus Sci Med. 2016 Sep 6;3(1):e000163. doi: 10.1136/lupus-2016-000163. eCollection 2016.

10.

Effects of two different exercise programs on chronic fatigue in lupus patients.

Avaux M, Hoellinger P, Nieuwland-Husson S, Fraselle V, Depresseux G, Houssiau FA.

Acta Clin Belg. 2016 Dec;71(6):403-406. Epub 2016 Jul 1.

PMID:
27377292
11.

Interferon α kinoid induces neutralizing anti-interferon α antibodies that decrease the expression of interferon-induced and B cell activation associated transcripts: analysis of extended follow-up data from the interferon α kinoid phase I/II study.

Ducreux J, Houssiau FA, Vandepapelière P, Jorgensen C, Lazaro E, Spertini F, Colaone F, Roucairol C, Laborie M, Croughs T, Grouard-Vogel G, Lauwerys BR.

Rheumatology (Oxford). 2016 Oct;55(10):1901-5. doi: 10.1093/rheumatology/kew262. Epub 2016 Jun 28.

12.

Why will lupus nephritis trials not fail anymore?

Houssiau FA.

Rheumatology (Oxford). 2017 May 1;56(5):677-678. doi: 10.1093/rheumatology/kew252. No abstract available.

PMID:
27338083
13.

Higher expression of TNFα-induced genes in the synovium of patients with early rheumatoid arthritis correlates with disease activity, and predicts absence of response to first line therapy.

De Groof A, Ducreux J, Humby F, Nzeusseu Toukap A, Badot V, Pitzalis C, Houssiau FA, Durez P, Lauwerys BR.

Arthritis Res Ther. 2016 Jan 20;18:19. doi: 10.1186/s13075-016-0919-z.

14.

Moving East: the Euro-Lupus Nephritis regimen in Asia.

Houssiau FA.

Kidney Int. 2016 Jan;89(1):25-7. doi: 10.1016/j.kint.2015.11.003.

PMID:
26759044
15.

Drug-induced lupus erythematosus mimicking lymphoma on 18F-FDG-PET/CT.

Guischer N, Houssiau FA, Lhommel R, Coche E, Roelants V.

Lupus. 2017 Jul;26(8):898-899. doi: 10.1177/0961203316682857. Epub 2016 Dec 20. No abstract available.

PMID:
28420045
16.

A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial.

Tamirou F, Lauwerys BR, Dall'Era M, Mackay M, Rovin B, Cervera R, Houssiau FA; MAINTAIN Nephritis Trial Investigators.

Lupus Sci Med. 2015 Nov 12;2(1):e000123. doi: 10.1136/lupus-2015-000123. eCollection 2015.

17.

Targeting BAFF/BLyS in lupus: is the glass half-full or half-empty?

Houssiau FA, Doria A.

Ann Rheum Dis. 2016 Feb;75(2):321-2. doi: 10.1136/annrheumdis-2015-208312. Epub 2015 Nov 20. No abstract available.

PMID:
26590173
18.

Heterogeneity of synovial molecular patterns in patients with arthritis.

Lauwerys BR, Hernández-Lobato D, Gramme P, Ducreux J, Dessy A, Focant I, Ambroise J, Bearzatto B, Nzeusseu Toukap A, Van den Eynde BJ, Elewaut D, Gala JL, Durez P, Houssiau FA, Helleputte T, Dupont P.

PLoS One. 2015 Apr 30;10(4):e0122104. doi: 10.1371/journal.pone.0122104. eCollection 2015.

19.

Crossing the Atlantic: the Euro-Lupus Nephritis regimen in North America.

Wofsy D, Diamond B, Houssiau FA.

Arthritis Rheumatol. 2015 May;67(5):1144-6. doi: 10.1002/art.39067. No abstract available.

20.

Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis.

Tamirou F, D'Cruz D, Sangle S, Remy P, Vasconcelos C, Fiehn C, Ayala Guttierez Mdel M, Gilboe IM, Tektonidou M, Blockmans D, Ravelingien I, le Guern V, Depresseux G, Guillevin L, Cervera R, Houssiau FA; MAINTAIN Nephritis Trial Group.

Ann Rheum Dis. 2016 Mar;75(3):526-31. doi: 10.1136/annrheumdis-2014-206897. Epub 2015 Mar 10.

21.

Unusual case of tetraparesis in a patient with systemic lupus erythematosus.

Ishchenko A, Malghem J, Banse X, Houssiau FA.

Lupus. 2015 Jun;24(7):760-3. doi: 10.1177/0961203314567752. Epub 2015 Jan 27.

PMID:
25631855
22.

Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort.

Dall'Era M, Cisternas MG, Smilek DE, Straub L, Houssiau FA, Cervera R, Rovin BH, Mackay M.

Arthritis Rheumatol. 2015 May;67(5):1305-13. doi: 10.1002/art.39026.

23.

Biologic therapy in lupus nephritis.

Houssiau FA.

Nephron Clin Pract. 2014;128(3-4):255-60. doi: 10.1159/000368587. Epub 2014 Nov 11. Review.

24.

sIL7R concentrations in the serum reflect disease activity in the lupus kidney.

Lauwerys BR, Husson SN, Maudoux AL, Badot V, Houssiau FA.

Lupus Sci Med. 2014 Jul 17;1(1):e000036. doi: 10.1136/lupus-2014-000036. eCollection 2014.

25.

So much hope for lupus, at last.

Houssiau FA.

Presse Med. 2014 Jun;43(6 Pt 2):e141. doi: 10.1016/j.lpm.2014.05.001. Epub 2014 Jun 2. No abstract available.

PMID:
24933677
26.

Response to letter by Aramugakani et al.

Ferraccioli G, Houssiau FA.

Ann Rheum Dis. 2014 Apr;73(4):e21. doi: 10.1136/annrheumdis-2013-205128. Epub 2014 Jan 30. No abstract available.

PMID:
24482300
27.

Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium.

Ducreux J, Durez P, Galant C, Nzeusseu Toukap A, Van den Eynde B, Houssiau FA, Lauwerys BR.

Arthritis Rheumatol. 2014 Jan;66(1):15-23. doi: 10.1002/art.38202.

28.

Type I interferon blockade in systemic lupus erythematosus: where do we stand?

Lauwerys BR, Ducreux J, Houssiau FA.

Rheumatology (Oxford). 2014 Aug;53(8):1369-76. doi: 10.1093/rheumatology/ket403. Epub 2013 Dec 15. Review.

PMID:
24344319
29.

Prognosis of proliferative lupus nephritis subsets in the Louvain Lupus Nephritis inception Cohort.

Vandepapelière J, Aydin S, Cosyns JP, Depresseux G, Jadoul M, Houssiau FA.

Lupus. 2014 Feb;23(2):159-65. doi: 10.1177/0961203313514623. Epub 2013 Dec 3.

PMID:
24300780
30.

Current management of lupus nephritis.

Houssiau FA, Lauwerys BR.

Best Pract Res Clin Rheumatol. 2013 Jun;27(3):319-28. doi: 10.1016/j.berh.2013.07.004. Review.

PMID:
24238689
31.

Editorial: Advances in SLE--an innovative era for patients and clinicians.

D'Cruz D, Houssiau FA.

Best Pract Res Clin Rheumatol. 2013 Jun;27(3):307-8. doi: 10.1016/j.berh.2013.08.001. Epub 2013 Sep 5. No abstract available.

PMID:
24238687
32.

Which B-cell subset should we target in lupus?

Ferraccioli G, Houssiau FA.

Ann Rheum Dis. 2013 Dec;72(12):1891-2. doi: 10.1136/annrheumdis-2013-203827. No abstract available.

PMID:
24191067
33.

Towards treating lupus nephritis without oral steroids: a dream-come-true?

Houssiau FA, Isenberg D.

Ann Rheum Dis. 2013 Aug;72(8):1271-2. doi: 10.1136/annrheumdis-2013-203205. No abstract available.

PMID:
23828303
34.

Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study.

Mysler EF, Spindler AJ, Guzman R, Bijl M, Jayne D, Furie RA, Houssiau FA, Drappa J, Close D, Maciuca R, Rao K, Shahdad S, Brunetta P.

Arthritis Rheum. 2013 Sep;65(9):2368-79. doi: 10.1002/art.38037.

35.

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study.

Wallace DJ, Kalunian K, Petri MA, Strand V, Houssiau FA, Pike M, Kilgallen B, Bongardt S, Barry A, Kelley L, Gordon C.

Ann Rheum Dis. 2014 Jan;73(1):183-90. doi: 10.1136/annrheumdis-2012-202760. Epub 2013 Jan 12.

36.

Serum soluble interleukin 7 receptor is strongly associated with lupus nephritis in patients with systemic lupus erythematosus.

Badot V, Luijten RK, van Roon JA, Depresseux G, Aydin S, Van den Eynde BJ, Houssiau FA, Lauwerys BR.

Ann Rheum Dis. 2013 Mar;72(3):453-6. doi: 10.1136/annrheumdis-2012-202364. Epub 2012 Dec 22.

37.

Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid.

Lauwerys BR, Hachulla E, Spertini F, Lazaro E, Jorgensen C, Mariette X, Haelterman E, Grouard-Vogel G, Fanget B, Dhellin O, Vandepapelière P, Houssiau FA.

Arthritis Rheum. 2013 Feb;65(2):447-56. doi: 10.1002/art.37785.

38.

Tendon friction rubs in systemic sclerosis: a possible explanation--an ultrasound and magnetic resonance imaging study.

Stoenoiu MS, Houssiau FA, Lecouvet FE.

Rheumatology (Oxford). 2013 Mar;52(3):529-33. doi: 10.1093/rheumatology/kes307. Epub 2012 Nov 28.

PMID:
23192909
39.

The Belgian Systemic Sclerosis Cohort: correlations between disease severity scores, cutaneous subsets, and autoantibody profile.

Vanthuyne M, Smith V, De Langhe E, Van Praet J, Arat S, Depresseux G, Westhovens R, Blockmans D, Badot V, Cogan E, De Keyser F, Houssiau FA.

J Rheumatol. 2012 Nov;39(11):2127-33. doi: 10.3899/jrheum.120283. Epub 2012 Sep 15.

PMID:
22984273
40.

Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis.

Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, Boletis J, Cervera R, Dörner T, Doria A, Ferrario F, Floege J, Houssiau FA, Ioannidis JP, Isenberg DA, Kallenberg CG, Lightstone L, Marks SD, Martini A, Moroni G, Neumann I, Praga M, Schneider M, Starra A, Tesar V, Vasconcelos C, van Vollenhoven RF, Zakharova H, Haubitz M, Gordon C, Jayne D, Boumpas DT; European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association.

Ann Rheum Dis. 2012 Nov;71(11):1771-82. doi: 10.1136/annrheumdis-2012-201940. Epub 2012 Jul 31.

41.

Therapy of lupus nephritis: lessons learned from clinical research and daily care of patients.

Houssiau FA.

Arthritis Res Ther. 2012 Jan 31;14(1):202. doi: 10.1186/ar3656. Review.

42.

Repeat kidney biopsies fail to detect differences between azathioprine and mycophenolate mofetil maintenance therapy for lupus nephritis: data from the MAINTAIN Nephritis Trial.

Stoenoiu MS, Aydin S, Tektonidou M, Ravelingien I, le Guern V, Fiehn C, Remy P, Delahousse M, Petera P, Quémeneur T, Vasconcelos C, D'Cruz D, Gilboe IM, Jadoul M, Karras A, Depresseux G, Guillevin L, Cervera R, Cosyns JP, Houssiau FA; MAINTAIN Nephritis Trial Group.

Nephrol Dial Transplant. 2012 May;27(5):1924-30. doi: 10.1093/ndt/gfr553. Epub 2011 Nov 22.

PMID:
22110048
43.

Toward better treatment for lupus nephritis.

Houssiau FA.

N Engl J Med. 2011 Nov 17;365(20):1929-30. doi: 10.1056/NEJMe1111089. No abstract available.

PMID:
22087685
44.

The association of illness perceptions with physical and mental health in systemic sclerosis patients: an exploratory study.

Arat S, Verschueren P, De Langhe E, Smith V, Vanthuyne M, Diya L, Van den Heede K, Blockmans D, De Keyser F, Houssiau FA, Westhovens R.

Musculoskeletal Care. 2012 Mar;10(1):18-28. doi: 10.1002/msc.223. Epub 2011 Nov 11.

PMID:
22076953
45.

Rituximab treatment induces the expression of genes involved in healing processes in the rheumatoid arthritis synovium.

Gutierrez-Roelens I, Galant C, Theate I, Lories RJ, Durez P, Nzeusseu-Toukap A, Van den Eynde B, Houssiau FA, Lauwerys BR.

Arthritis Rheum. 2011 May;63(5):1246-54. doi: 10.1002/art.30292.

46.

Rheumatoid arthritis synovial fibroblasts produce a soluble form of the interleukin-7 receptor in response to pro-inflammatory cytokines.

Badot V, Durez P, Van den Eynde BJ, Nzeusseu-Toukap A, Houssiau FA, Lauwerys BR.

J Cell Mol Med. 2011 Nov;15(11):2335-42. doi: 10.1111/j.1582-4934.2010.01228.x.

47.

Hand radiological damage in systemic sclerosis: comparison with a control group and clinical and functional correlations.

Koutaissoff S, Vanthuyne M, Smith V, De Langhe E, Depresseux G, Westhovens R, De Keyser F, Malghem J, Houssiau FA.

Semin Arthritis Rheum. 2011 Apr;40(5):455-60. doi: 10.1016/j.semarthrit.2010.06.008. Epub 2010 Sep 22.

PMID:
20864145
48.

Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial.

Houssiau FA, D'Cruz D, Sangle S, Remy P, Vasconcelos C, Petrovic R, Fiehn C, de Ramon Garrido E, Gilboe IM, Tektonidou M, Blockmans D, Ravelingien I, le Guern V, Depresseux G, Guillevin L, Cervera R; MAINTAIN Nephritis Trial Group.

Ann Rheum Dis. 2010 Dec;69(12):2083-9. doi: 10.1136/ard.2010.131995. Epub 2010 Sep 10.

49.

Mesenchymal stem cells in the treatment of autoimmune diseases.

Tyndall A, Houssiau FA.

Ann Rheum Dis. 2010 Aug;69(8):1413-4. doi: 10.1136/ard.2010.132639. No abstract available.

PMID:
20650875
50.

Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database.

Avouac J, Walker U, Tyndall A, Kahan A, Matucci-Cerinic M, Allanore Y; EUSTAR, Miniati I, Muller A, Iannone F, Distler O, Becvar R, Sierakowsky S, Kowal-Bielecka O, Coelho P, Cabane J, Cutolo M, Shoenfeld Y, Valentini G, Rovensky J, Riemekasten G, Vlachoyiannopoulos P, Caporali R, Jiri S, Inanc M, Zimmermann Gorska I, Carreira P, Novak S, Czirjak L, Oliveira Ramos F, Jendro M, Chizzolini C, Kucharz EJ, Richter J, Cozzi F, Rozman B, Mallia CM, Gabrielli A, Farge D, Kiener HP, Schöffel D, Airo P, Wollheim F, Martinovic D, Trotta F, Jablonska S, Reich K, Bombardieri S, Siakka P, Pellerito R, Bambara LM, Morovic-Vergles J, Denton C, Hinrichs R, Van den Hoogen F, Damjanov N, Kötter I, Ortiz V, Heitmann S, Krasowska D, Seidel M, Hasler P, Van Laar JM, Kaltwasser JP, Foeldvari I, Juan Mas A, Bajocchi G, Wislowska M, Pereira Da Silva JA, Jacobsen S, Worm M, Graniger W, Kuhn A, Stankovic A, Cossutta R, Majdan M, Damjanovska Rajcevska L, Tikly M, Nasonov EL, Steinbrink K, Herrick A, Müller-Ladner U, Dinc A, Scorza R, Sondergaard K, Indiveri F, Nielsen H, Szekanecz Z, Silver RM, Antivalle M, Espinosa IB, García de la Pena Lefebvre P, Midtvedt O, Launay D, Valesini F, Tuvik P, Ionescu RM, Del Papa N, Pinto S, Wigley F, Mihai C, Sinziana Capranu M, Sunderkötter C, Jun JB, Alhasani S, Distler JH, Ton E, Soukup T, Seibold J, Zeni S, Nash P, Mouthon L, De Keyser F, Duruöz MT, Cantatore FP, Strauss G, von Mülhen CA, Pozzi MR, Eyerich K, Szechinski J, Keiserman M, Houssiau FA, Román-Ivorra JA, Krummel-Lorenz B, Aringer M, Westhovens R, Bellisai F, Mayer M, Stoeckl F, Uprus M, Volpe A, Buslau M, Yavuz S, Granel B, Valderílio Feijó A, Del Galdo F, Popa S, Zenone T, Ricardo Machado X, Pileckyte M, Stebbings S, Mathieu A, Tulli A, Tourinho T, Souza R, Acayaba de Toledo R, Stamp L, Solanki K, Veale D, Francisco Marques Neto J, Bagnato GF, Loyo E, Toloza S, Li M, Ahmed Abdel Atty Mohamed W, Cobankara V, Olas J, Salsano F, Oksel F, Tanaseanu CM, Foti R, Ancuta C, Vonk M, Caramashi P, Beretta L, Balbir A, Chiàla A, Pasalic Simic K, Ghio M, Stamenkovic B, Rednic S, Host N, Pellerito R, Hachulla E, Furst DE.

J Rheumatol. 2010 Jul;37(7):1488-501. doi: 10.3899/jrheum.091165. Epub 2010 Jun 15.

PMID:
20551097

Supplemental Content

Loading ...
Support Center